{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:06:28Z","timestamp":1779440788493,"version":"3.53.1"},"reference-count":24,"publisher":"Informa UK Limited","funder":[{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Scandinavian Journal of Rheumatology"],"DOI":"10.1080\/03009742.2026.2666987","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T08:30:32Z","timestamp":1779438632000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal patterns of C-reactive protein values in calcium pyrophosphate deposition disease"],"prefix":"10.1080","author":[{"given":"M","family":"Gill","sequence":"first","affiliation":[{"name":"Brigham and Women\u2019s Hospital","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Guan","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8413-007X","authenticated-orcid":false,"given":"JE","family":"Collins","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9475-1363","authenticated-orcid":false,"given":"SK","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/art.42798","article-title":"Fractures in patients with acute calcium pyrophosphate crystal arthritis versus matched comparators in a large cohort study","volume":"76","author":"Tedeschi SK","year":"2024","unstructured":"Tedeschi SK, Hayashi K, Rosenthal A, Gill M, Marrugo J, Fukui S, et al. Fractures in patients with acute calcium pyrophosphate crystal arthritis versus matched comparators in a large cohort study. Arthritis Rheumatol 2024;76:936\u201341.","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_6_3_1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11926-015-0496-1","article-title":"Imaging of calcium pyrophosphate deposition disease","volume":"17","author":"Miksanek J","year":"2015","unstructured":"Miksanek J, Rosenthal AK. Imaging of calcium pyrophosphate deposition disease. Curr Rheumatol Rep 2015;17:20.","journal-title":"Curr Rheumatol Rep"},{"key":"e_1_3_6_4_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/OARRR.S389664","article-title":"Diagnosis and treatment of calcium pyrophosphate deposition (CPPD) disease: a review","volume":"15","author":"Cowley S","year":"2023","unstructured":"Cowley S, McCarthy G. Diagnosis and treatment of calcium pyrophosphate deposition (CPPD) disease: a review. Open Access Rheumatol 2023;15:33\u201341.","journal-title":"Open Access Rheumatol"},{"key":"e_1_3_6_5_1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/art.42619","article-title":"The 2023 ACR\/EULAR classification criteria for calcium pyrophosphate deposition disease","volume":"75","author":"Abhishek A","year":"2023","unstructured":"Abhishek A, Tedeschi SK, Pascart T, Latourte A, Dalbeth N, Neogi T, et al. The 2023 ACR\/EULAR classification criteria for calcium pyrophosphate deposition disease. Arthritis Rheumatol 2023;75:1703\u201313.","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_6_6_1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/gucdd2010005","article-title":"A new era for calcium pyrophosphate deposition disease research: the first-ever calcium pyrophosphate deposition disease classification criteria and considerations for measuring outcomes in calcium pyrophosphate deposition disease","volume":"2","author":"Tedeschi SK","year":"2024","unstructured":"Tedeschi SK. A new era for calcium pyrophosphate deposition disease research: the first-ever calcium pyrophosphate deposition disease classification criteria and considerations for measuring outcomes in calcium pyrophosphate deposition disease. Gout, Urate, and Crystal Deposition Disease 2024;2:52\u20139.","journal-title":"Gout, Urate, and Crystal Deposition Disease"},{"key":"e_1_3_6_7_1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/ard.2010.139105","article-title":"European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: Terminology and diagnosis","volume":"70","author":"Zhang W","year":"2011","unstructured":"Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: Terminology and diagnosis. Ann Rheum Dis 2011;70:563\u201370.","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_6_8_1","doi-asserted-by":"crossref","first-page":"e791","DOI":"10.1016\/S2665-9913(24)00122-X","article-title":"Calcium pyrophosphate deposition disease","volume":"6","author":"Pascart T","year":"2024","unstructured":"Pascart T, Filippou G, Liote F, Sirotti S, Jauffret C, Abhishek A. Calcium pyrophosphate deposition disease. Lancet Rheumatol 2024;6:e791\u2013e804.","journal-title":"Lancet Rheumatol"},{"key":"e_1_3_6_9_1","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.2147\/JIR.S432898","article-title":"New inflammatory marker associated with disease activity in gouty arthritis: the Systemic Inflammatory Response Index","volume":"16","author":"Jiang Y","year":"2023","unstructured":"Jiang Y, Tu X, Liao X, He Y, Wang S, Zhang Q, et al. New inflammatory marker associated with disease activity in gouty arthritis: the Systemic Inflammatory Response Index. J Inflamm Res 2023;16:5565\u201373.","journal-title":"J Inflamm Res"},{"key":"e_1_3_6_10_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.semarthrit.2020.11.005","article-title":"C-reactive protein and implications in rheumatoid arthritis and associated comorbidities","volume":"51","author":"Pope JE","year":"2021","unstructured":"Pope JE, Choy EH. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum 2021;51:219\u201329.","journal-title":"Semin Arthritis Rheum"},{"key":"e_1_3_6_11_1","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1016\/S2665-9913(23)00165-0","article-title":"Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial","volume":"5","author":"Pascart T","year":"2023","unstructured":"Pascart T, Robinet P, Ottaviani S, Leroy R, Segaud N, Pacaud A, et al. Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial. Lancet Rheumatol 2023;5:e523\u201331.","journal-title":"Lancet Rheumatol"},{"key":"e_1_3_6_12_1","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","article-title":"Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate","volume":"68","author":"Wells G","year":"2009","unstructured":"Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954\u201360.","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_6_13_1","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3899\/jrheum.2023-0031","article-title":"Patient-reported outcomes in calcium pyrophosphate deposition disease compared to gout and osteoarthritis","volume":"50","author":"Whelan MG","year":"2023","unstructured":"Whelan MG, Hayashi K, Altwies H, Tedeschi SK. Patient-reported outcomes in calcium pyrophosphate deposition disease compared to gout and osteoarthritis. J Rheumatol 2023;50:1058\u201362.","journal-title":"J Rheumatol"},{"key":"e_1_3_6_14_1","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/acr.24132","article-title":"Classifying pseudogout using machine learning approaches with electronic health record data","volume":"73","author":"Tedeschi SK","year":"2021","unstructured":"Tedeschi SK, Cai T, He Z, Ahuja Y, Hong C, Yates KA, et al. Classifying pseudogout using machine learning approaches with electronic health record data. Arthritis Care Res (Hoboken) 2021;73:442\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"e_1_3_6_15_1","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1161\/01.CIR.103.13.1813","article-title":"High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease","volume":"103","author":"Ridker PM","year":"2001","unstructured":"Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813\u201318.","journal-title":"Circulation"},{"key":"e_1_3_6_16_1","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/s13075-014-0458-4","article-title":"Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial","volume":"16","author":"Finckh A","year":"2014","unstructured":"Finckh A, Mc Carthy GM, Madigan A, Van Linthoudt D, Weber M, Neto D, et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther 2014;16:458.","journal-title":"Arthritis Res Ther"},{"key":"e_1_3_6_17_1","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41598-023-50951-2","article-title":"Longitudinal changes in high sensitivity C-reactive protein associated with serum uric acid in the Korean Genome and Epidemiology Study","volume":"14","author":"Kityo A","year":"2024","unstructured":"Kityo A, Lee SA. Longitudinal changes in high sensitivity C-reactive protein associated with serum uric acid in the Korean Genome and Epidemiology Study. Sci Rep 2024;14:374.","journal-title":"Sci Rep"},{"key":"e_1_3_6_18_1","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/rheumatology\/keae533","article-title":"Systemic inflammation in asymptomatic hyperuricemia with sonographic crystal deposits, including a comparison with normouricemia and gout","volume":"64","author":"Peral-Garrido ML","year":"2024","unstructured":"Peral-Garrido ML, Gomez-Sabater S, Cano R, Bermudez-Garcia A, Boix P, Lozano T, et al. Systemic inflammation in asymptomatic hyperuricemia with sonographic crystal deposits, including a comparison with normouricemia and gout. Rheumatology (Oxford) 2024;64:1807\u201316.","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_3_6_19_1","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1002\/acr.23549","article-title":"Levels of cytokines and microRNAs in individuals with asymptomatic hyperuricemia and ultrasonographic findings of gout: a bench-to-bedside approach","volume":"70","author":"Estevez-Garcia IO","year":"2018","unstructured":"Estevez-Garcia IO, Gallegos-Nava S, Vera-Perez E, Silveira LH, Ventura-Rios L, Vancini G, et al. Levels of cytokines and microRNAs in individuals with asymptomatic hyperuricemia and ultrasonographic findings of gout: a bench-to-bedside approach. Arthritis Care Res (Hoboken) 2018;70:1814\u201321.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"e_1_3_6_20_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.semarthrit.2020.10.005","article-title":"Management of calcium pyrophosphate crystal deposition disease: a systematic review","volume":"51","author":"Parperis K","year":"2021","unstructured":"Parperis K, Papachristodoulou E, Kakoullis L, Rosenthal AK. Management of calcium pyrophosphate crystal deposition disease: a systematic review. Semin Arthritis Rheum 2021;51:84\u201394.","journal-title":"Semin Arthritis Rheum"},{"key":"e_1_3_6_21_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/gucdd3040022","article-title":"The Fast-evolving landscape of treatments for calcium pyrophosphate deposition disease","volume":"3","author":"Tai V","year":"2025","unstructured":"Tai V, Jauffret C, Dalbeth N, Pascart T. The Fast-evolving landscape of treatments for calcium pyrophosphate deposition disease. Gout, Urate, and Crystal Deposition Disease 2025;3:22.","journal-title":"Gout, Urate, and Crystal Deposition Disease"},{"key":"e_1_3_6_22_1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/rheumatology\/kead228","article-title":"Retention, safety and efficacy of off-label conventional treatments and biologics for chronic calcium pyrophosphate crystal inflammatory arthritis","volume":"63","author":"Damart J","unstructured":"Damart J, Filippou G, Andres M, Cipolletta E, Sirotti S, Carboni D, et al. Retention, safety and efficacy of off-label conventional treatments and biologics for chronic calcium pyrophosphate crystal inflammatory arthritis. Rheumatology (Oxford) 2024;63:446\u201355.","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_3_6_23_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s41927-022-00299-3","article-title":"Using the derived 28-joint Disease Activity Score Patient-reported components (DAS28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis","volume":"6","author":"Pisaniello HL","year":"2022","unstructured":"Pisaniello HL, Whittle SL, Lester S, Menz F, Metcalf R, McWilliams L, et al. Using the derived 28-joint Disease Activity Score Patient-reported components (DAS28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis. BMC Rheumatol 2022;6:67.","journal-title":"BMC Rheumatol"},{"key":"e_1_3_6_24_1","doi-asserted-by":"crossref","first-page":"e003317","DOI":"10.1136\/rmdopen-2023-003317","article-title":"The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis","volume":"9","author":"Kivitz A","year":"2023","unstructured":"Kivitz A, Wang L, Alevizos I, Gunsior M, Falloon J, Illei G, et al. The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis. RMD Open 2023;9:e003317.","journal-title":"RMD Open"},{"key":"e_1_3_6_25_1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s40001-024-01923-3","article-title":"Association of C-reactive protein with all-cause and cause-specific mortality in people with gout","volume":"29","author":"Han L","year":"2024","unstructured":"Han L, Zhang L, Hu W, Lu Y, Wang Z. Association of C-reactive protein with all-cause and cause-specific mortality in people with gout. Eur J Med Res 2024;29:320.","journal-title":"Eur J Med Res"}],"container-title":["Scandinavian Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03009742.2026.2666987","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T08:30:36Z","timestamp":1779438636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03009742.2026.2666987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":24,"alternative-id":["10.1080\/03009742.2026.2666987"],"URL":"https:\/\/doi.org\/10.1080\/03009742.2026.2666987","relation":{},"ISSN":["0300-9742","1502-7732"],"issn-type":[{"value":"0300-9742","type":"print"},{"value":"1502-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=irhe20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=irhe20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}